The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Open accessAbstract
BACKGROUND: CD19-specific chimeric antigen receptor (CAR) T cells induce high rates of initial response among patients with relapsed B-cell acute lymphoblastic leukemia (ALL) and long-term remissions in a subgroup of patients. METHODS: We conducted a phase 1 trial involving adults with relapsed B-cell ALL who received an infusion of autologous T cells expressing the 19-28z CAR at the Memorial Sloan Kettering Cancer Center (MSKCC). Safety and long-term outcomes were assessed, as were their associations with demographic, clinical, and disease characteristics. RESULTS: A total of 53 adults received 19-28z CAR T cells that were manufactured at MSKCC. After infusion, severe cytokine release syndrome occurred in 14 of 53 patients (26%; 95% confidence interval [CI], 15 to 40); 1 patient died. Complete remission was observed in 83% of the patients. At a median follow-up of 29 months (range, 1 to 65), the median event-free survival was 6.1 months (95% CI, 5.0 to 11.5), and the median overall survival was 12.9 months (95% CI, 8.7 to 23.4). Patients with a low disease burden (<5% bone marrow blasts) before treatment had markedly enhanced remission duration and survival, with a median event-free survival of 10.6 months (95% CI, 5.9 to not reached) and a median overall survival of 20.1 months (95% CI, 8.7 to not reached). Patients with a higher burden of disease (≥5% bone marrow blasts or extramedullary disease) had a greater incidence of the cytokine release syndrome and neurotoxic events and shorter long-term survival than did patients with a low disease burden. CONCLUSIONS: In the entire cohort, the median overall survival was 12.9 months. Among patients with a low disease burden, the median overall survival was 20.1 months and was accompanied by a markedly lower incidence of the cytokine release syndrome and neurotoxic events after 19-28z CAR T-cell infusion than was observed among patients with a higher disease burden. (Funded by the Commonwealth Foundation for Cancer Research and others; ClinicalTrials.gov number, NCT01044069 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It has been reported that CAR-T cell therapy shows high response rates to B-ALL patients in different age groups [117–119].”
From Immunosenescence: a key player in cancer development (2020) · cites this paper as [119]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Rivière, I., Wang, X., Bartido, S. M., Park, J. H., Curran, K. J., Chung, S. S., Stefanski, J., Bórquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,514
Self-citationBlinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Kantarjian, H. M., Stein, A. S., Gökbuget, N., Fielding, A. K., Schuh, A. C., Ribera, J., Wei, A. H., Dombret, H., Foà, R., Bassan, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609783 · Cited by 2,204
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Self-citationT-cell invigoration to tumour burden ratio associated with anti-PD-1 response
Huang, A. C., Postow, M. A., Orlowski, R. J., Mick, R., Bengsch, B., Manne, S., Xu, W., Harmon, S., Giles, J. R., Wenz, B., et al. (2017) · Nature · doi:10.1038/nature22079 · Cited by 1,664
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Martinelli, G., Liedtke, M., Stock, W., Gökbuget, N., O'Brien, S. M., Wang, K., Wang, T., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509277 · Cited by 1,444
Brentjens, R. J., Rivière, I., Park, J. H., Davila, M. L., Wang, X., Stefanski, J., Taylor, C., Yeh, R., Bartido, S. M., Bórquez-Ojeda, O., et al. (2011) · Blood · doi:10.1182/blood-2011-04-348540 · Cited by 1,293
Self-citationTopp, M. S., Kufer, P., Gökbuget, N., Goebeler, M., Klinger, M., Neumann, S., Horst, H.-A., Raff, T., Viardot, A., Schmid, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.7270 · Cited by 914
Flagged first, then by citations
Cited by
Sorted by citations
Items 901–1,000 of 1,004
Nair, M. S., Silbert, S. K., Rejeski, K., Wilson, K. A., Lamble, A. J., Valtis, Y. K., Yates, B., Arana, A. M., Shouval, R., Curran, K. J., et al. (2024) · Blood · doi:10.1182/blood.2024025910 · Cited by 33
Self-citationCD19 CAR-T cell therapy: a new dawn for autoimmune rheumatic diseases?
Rangel‐Peláez, C., Martínez-Gutiérrez, L., Tristán‐Manzano, M., Callejas-Rubio, J. L., Ortego‐Centeno, N., Martı́n, F., & Martin, J. J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1502712 · Cited by 32
Yakoub‐Agha, I., Moreau, A., Ahmad, I., Borel, C., Hadhoum, N., Masouridi‐Levrat, S., Naudin, J., Nicolas‐Virelizier, E., Ouachée-Chardin, M., Platon, L., et al. (2019) · Bulletin du Cancer · doi:10.1016/j.bulcan.2018.12.001 · Cited by 34
Recent Advances in Adult Acute Lymphoblastic Leukemia
Richard‐Carpentier, G., Kantarjian, H. M., & Jabbour, E. J. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-00503-1 · Cited by 31
Controlling Cytokine Release Syndrome to Harness the Full Potential of CAR-Based Cellular Therapy
Thakar, M. S., Kearl, T. J., & Malarkannan, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01529 · Cited by 32
Car-T Treatment for Hematological Malignancies
Atrash, S., Bano, K., Harrison, B. W., & Abdallah, A.-O. A. (2020) · Journal of Investigative Medicine · doi:10.1136/jim-2020-001290 · Cited by 32
CAR T cell therapy: newer approaches to counter resistance and cost
Yadav, R. K., Ali, A., Kumar, S., Sharma, A., Baghchi, B., Singh, P., Das, S., Singh, C., & Sharma, S. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e03779 · Cited by 32
Gu, B., Shi, B., Zhang, X., Zhou, S.-Y., Chu, J., Wu, X., Fu, C., Qiu, H., Han, Y., Chen, S., et al. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-0982-6 · Cited by 31
Chen, L., Kang, L., Zhou, H., Gao, H., Zhu, X., Xu, N., Yu, L., Wu, D., Xue, S., & Sun, A. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100838 · Cited by 31
Nanotechnology‐Based CAR‐T Strategies for Improving Efficacy and Safety of Tumor Immunotherapy
Wang, X., Meng, F., Yen, Y., Li, R., & Liu, B. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202004713 · Cited by 33
Self-citationTopp, M. S., Gökbuget, N., Zugmaier, G., Stein, A. S., Dombret, H., Chen, Y., Ribera, J., Bargou, R. C., Horst, H., & Kantarjian, H. M. (2020) · Cancer · doi:10.1002/cncr.33298 · Cited by 31
CAR T-cell therapy for pleural mesothelioma: Rationale, preclinical development, and clinical trials
Chintala, N. K., Restle, D. J., Quach, H. T., Saini, J. K., Bellis, R. Y., Offin, M. D., Beattie, J., & Adusumilli, P. S. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.05.004 · Cited by 31
Robust T cell activation requires an eIF3-driven burst in T cell receptor translation
Silva, D. D., Ferguson, L., Chin, G. H., Smith, B. E., Apathy, R., Roth, T. L., Blaeschke, F., Kudla, M., Marson, A., Ingolia, N. T., et al. (2021) · eLife · doi:10.7554/elife.74272 · Cited by 32
Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer
Crupi, M. J. F., Taha, Z., Janssen, T. J. A., Petryk, J., Boulton, S., Alluqmani, N., Jirovec, A., Kassas, O., Khan, S., Vallati, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1029269 · Cited by 31
Development of HIV-Resistant CAR T Cells by CRISPR/Cas-Mediated CAR Integration into the CCR5 Locus
Rothemejer, F. H., Lauritsen, N. P., Juhl, A. K., Schleimann, M. H., König, S., Søgaard, O. S., Bak, R. O., & Tolstrup, M. (2023) · Viruses · doi:10.3390/v15010202 · Cited by 31
Makita, S., Yamamoto, G., Maruyama, D., Asano‐Mori, Y., Kaji, D., Ananthakrishnan, R., Ogasawara, K., Stepan, L. P., Schusterbauer, C., Rettby, N., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.4820 · Cited by 30
Targeting CD22 for B-cell hematologic malignancies
Xu, J., Luo, W., Li, C., & Mei, H. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00454-7 · Cited by 31
Tang, L., Zhang, H., Zhou, F., Wei, Q., Du, M., Wu, J., Li, C., Luo, W., Zhou, J., Wang, X., et al. (2024) · 癌症：英文版 · doi:10.1002/cac2.12525 · Cited by 33
Self-citationSrinagesh, H. K., Jackson, C., Shiraz, P., Jeyakumar, N., Hamilton, M. P., Egeler, E. L., Mavroukakis, S. A., Kuo, A., Cancilla, J. E., Sahaf, B., et al. (2024) · Blood · doi:10.1182/blood.2024024952 · Cited by 30
Safety and efficacy of blinatumomab: a real world data
Apel, A., Ofran, Y., Wolach, O., Shimony, S. O., Ram, R., Levi, I., Zektser, M., & Koren‐Michowitz, M. (2020) · Annals of Hematology · doi:10.1007/s00277-019-03854-0 · Cited by 30
Cassaday, R. D., Garcia, K. A., Fromm, J. R., Percival, M. M., Turtle, C. J., Nghiem, P., Stevenson, P. A., & Estey, E. H. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002403 · Cited by 31
Exploring the food-gut axis in immunotherapy response of cancer patients
Russo, E., Nannini, G., Dinu, M., Pagliai, G., Sofi, F., & Amedei, A. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i33.4919 · Cited by 31
Kirchhoff, H., Karsli, U., Schoenherr, C., Battmer, K., Erschow, S., Talbot, S. R., Steinemann, D., Heuser, M., Heidenreich, O. T., Hilfiker‐Kleiner, D., et al. (2020) · Blood · doi:10.1182/blood.2020008544 · Cited by 30
CAR19/22 T cell therapy in adult refractory Burkitt’s lymphoma
Zhou, X., Ge, T., Li, T., Huang, L., Cao, Y., Xiao, Y., Zhen, M., Chen, L., & Zhou, J. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02850-6 · Cited by 30
Perspectives in membranous nephropathy
Tomas, N. M., Huber, T. B., & Hoxha, E. (2021) · Cell and Tissue Research · doi:10.1007/s00441-021-03429-4 · Cited by 30
Wang, S., Sellner, L., Wang, L., Sauer, T., Neuber, B., Gong, W., Stock, S., Ni, M., Yao, H., Kleist, C., et al. (2021) · Oncology Reports · doi:10.3892/or.2021.8121 · Cited by 30
An, L., Lin, Y., Deng, B., Yin, Z., Zhao, D., Ling, Z., Wu, T., Zhao, Y., Chang, A. H., Tong, C., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-09489-1 · Cited by 30
Lee, D. C., Jordan, A. I., Menges, M. A., Lazaryan, A., Nishihori, T., Gaballa, S. R., Shah, B. D., Pinilla-Ibarz, J. A., Baluch, A., Klinkova, O. V., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.08.011 · Cited by 30
Advances in natural killer cell therapies for breast cancer
Kiaei, S. Z. F., Nouralishahi, A., Ghasemirad, M., Barkhordar, M., Ghaffari, S., Kheradjoo, H., Saleh, M., Mohammadzadehsaliani, S., & Molaeipour, Z. (2023) · Immunology and Cell Biology · doi:10.1111/imcb.12658 · Cited by 30
Katiyar, V., Chesney, J. A., & Kloecker, G. H. (2023) · Cancers · doi:10.3390/cancers15143733 · Cited by 32
Avouac, J., Cauvet, A., Orvain, C., Boulch, M., Tilotta, F., Tu, L., Thuillet, R., Ottaviani, M., Guignabert, C., Bousso, P., et al. (2023) · Arthritis & Rheumatology · doi:10.1002/art.42677 · Cited by 30
Luo, Y., Gao, L., Liu, J., Yang, L., Wang, L., Lai, X., Gao, S., Liu, L., Zhao, L., Ye, Y., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102377 · Cited by 30
CAR-T CELL THERAPY IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Testa, U., Sica, S., Pelosi, E., Castelli, G., & Leone, G. G. M. (2024) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2024.010 · Cited by 33
Targeted therapy paves the way for the cure of acute lymphoblastic leukaemia
Rafei, H., Kantarjian, H. M., & Jabbour, E. J. (2019) · British Journal of Haematology · doi:10.1111/bjh.16207 · Cited by 32
Enterotoxins can support CAR T cells against solid tumors
von Scheidt, B., Wang, M., Oliver, A. J., Chan, J. D., Jana, M. K., Ali, A. I., Clow, F., Fraser, J. D., Quinn, K. M., Darcy, P. K., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1904618116 · Cited by 30
Incidence of MACE in Patients Treated With CAR-T Cell Therapy
Lefebvre, B., Kang, Y., Vakilpour, A., Onoue, T., Frey, N. V., Brahmbhatt, P., Huang, B. Z., Oladuja, K., Koropeckyj-Cox, D., Wiredu, C., et al. (2023) · JACC CardioOncology · doi:10.1016/j.jaccao.2023.07.009 · Cited by 29
Leukapheresis for CAR-T cell production and therapy
Pessach, I., & Nagler, A. (2023) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2023.103828 · Cited by 32
Combined use of NK cells and radiotherapy in the treatment of solid tumors
Wang, Z., Ling, S., Cao, Y., Shao, C., & Sun, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1306534 · Cited by 29
Barriers to CAR T-cell therapy in rheumatology
Lungova, K., & Putman, M. (2024) · The Lancet Rheumatology · doi:10.1016/s2665-9913(24)00240-6 · Cited by 29
Mechanisms of antigen-dependent resistance to chimeric antigen receptor (CAR)-T cell therapies
Nasiri, F., Kozani, P. S., Salem, F., Kancha, M. M., Shokoohi, S. D., & Kozani, P. S. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03697-y · Cited by 30
Shang, Y., & Zhou, F. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00917 · Cited by 29
Leung, K. T., Zhang, C., Chan, K. Y. Y., Li, K., Cheung, J. T. K., Ng, M. H. L., Zhang, X., Sit, T., Lee, W., Kang, W., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0593-7 · Cited by 30
Novel Therapies in the Treatment of Adult Acute Lymphoblastic Leukemia
Gavralidis, A., & Brunner, A. M. (2020) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-020-00591-4 · Cited by 29
Engineering Cytoplasmic Signaling of CD28ζ CARs for Improved Therapeutic Functions
Meng, X., Jing, R., Qian, L., Zhou, C., & Sun, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01046 · Cited by 31
Advances in chimeric antigen receptor T cells
Beyar‐Katz, O., & Gill, S. I. (2020) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000614 · Cited by 29
Furukawa, Y., Hamano, Y., Shirane, S., Kinoshita, S., Azusawa, Y., Ando, J., Nakauchi, H., & Ando, M. (2022) · Cells · doi:10.3390/cells11020269 · Cited by 29
Synthetic Biology in Chimeric Antigen Receptor T (CAR T) Cell Engineering
Zhang, C., Zhuang, Q., Liu, J., & Liu, X. (2022) · ACS Synthetic Biology · doi:10.1021/acssynbio.1c00256 · Cited by 29
Beider, K., Itzhaki, O., Schachter, J., Grushchenko-Polaq, A. H., Voevoda-Dimenshtein, V., Rosenberg, E., Ostrovsky, O., Devillers, O., Frommer, R. S., Zeltzer, L., et al. (2022) · Cells · doi:10.3390/cells11071140 · Cited by 30
Nakazawa, T., Morimoto, T., Maeoka, R., Matsuda, R., Nakamura, M., Nishimura, F., Yamada, S., Nakagawa, I., Park, Y.-S., Nakase, H., et al. (2022) · Regenerative Therapy · doi:10.1016/j.reth.2022.07.001 · Cited by 29
Butt, O. H., Zhou, A. Y., Caimi, P. F., Luckett, P. H., Wisch, J. K., Derenoncourt, P.-R., Lee, K., Wu, G. F., Lima, M. J. G. D., Campian, J. L., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.3738 · Cited by 29
Camilli, M., Maggio, L., Tinti, L., Lamendola, P., Lanza, G. A., Crea, F., & Lombardo, A. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1090103 · Cited by 29
Niu, J., Qiu, H., Fang, X., Zhu, L., Yang, J. J. J., Huang, C., Zhou, K. L., Yin, T., Cai, Y., Dong, B., et al. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00813-x · Cited by 29
Coengineering specificity, safety, and function into T cells for cancer immunotherapy
Attianese, G. M. P. G., Ash, S., & Irving, M. B. (2023) · Immunological Reviews · doi:10.1111/imr.13252 · Cited by 29
Hunger, J., Schregel, K., Boztepe, B., Agardy, D. A., Turco, V., Jazi, K. K., Weidenfeld, I., Streibel, Y., Fischer, M. D., Sturm, V. J. F., et al. (2023) · Theranostics · doi:10.7150/thno.87248 · Cited by 29
Dynamic Profiling of Antitumor Activity of CAR T Cells Using Micropatterned Tumor Arrays
Wang, X., Scarfò, I., Schmidts, A., Toner, M., Maus, M. V., & Irimia, D. (2019) · Advanced Science · doi:10.1002/advs.201901829 · Cited by 29
Self-citationDu, J., & Zhang, Y. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03269-9 · Cited by 29
Locatelli, F., Shah, B. D., Thomas, T., Velasco, K., Adedokun, B., Aldoss, I. T., Gore, L., Hoelzer, D. F., Bassan, R., Park, J. H., et al. (2023) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2023.2232496 · Cited by 29
Self-citationZhou, J., Shi, F., Luo, X., Lei, B., Shi, Z., Huang, C., Zhang, Y., Li, X., Wang, H., Li, X.-Y., et al. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111239 · Cited by 29
Hickey, J. W., Agmon, E., Horowitz, N. B., Tan, T.-K., Lamore, M., Sunwoo, J. B., Covert, M. W., & Nolan, G. P. (2024) · Cell Systems · doi:10.1016/j.cels.2024.03.004 · Cited by 32
Thavorn, K., Thompson, E. R., Kumar, S., Heiskanen, A., Agarwal, A., Atkins, H. L., Shorr, R., Hawrysh, T., Chan, K., Presseau, J., et al. (2024) · Value in Health · doi:10.1016/j.jval.2024.04.004 · Cited by 28
Optimisation of a primary human CAR‐NK cell manufacturing pipeline
Pfefferle, A., Contet, J., Wong, K., Chen, C., Verhoeyen, E., Slichter, C. K., Schluns, K. S., Cursons, J., Berry, R., Nikolić, I., et al. (2024) · Clinical & Translational Immunology · doi:10.1002/cti2.1507 · Cited by 28
Beginning the CAR T cell therapy revolution in the US and EU
Grupp, S. A. (2018) · Current Research in Translational Medicine · doi:10.1016/j.retram.2018.03.004 · Cited by 28
Maruta, M., Ochi, T., Tanimoto, K., Asai, H., Saitou, T., Fujiwara, H., Imamura, T., Takenaka, K., & Yasukawa, M. (2019) · Scientific Reports · doi:10.1038/s41598-019-49834-2 · Cited by 28
Chen, G. M., Azzam, A., Ding, Y., Barrett, D. M., Grupp, S. A., & Tan, K. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3888 · Cited by 28
Feasibility of leukapheresis for CAR T-cell production in heavily pre-treated pediatric patients
Hutt, D., Bielorai, B., Baturov, B., Z’orbinski, I., Ilin, N., Adam, E., Itzhaki, O., Besser, M. J., Toren, A., & Jacoby, E. (2020) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2020.102769 · Cited by 28
Does lineage plasticity enable escape from CAR-T cell therapy? Lessons from MLL-r leukemia
Liao, W., Kohler, M. E., Fry, T. J., & Ernst, P. (2021) · Experimental Hematology · doi:10.1016/j.exphem.2021.07.002 · Cited by 29
Advances in mRNA-based drug discovery in cancer immunotherapy
Trani, C. A. D., Fernández-Sendin, M., Cirella, A., Segués, A., Olivera, I., Bolaños, E., Melero, I., & Berraondo, P. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1978972 · Cited by 28
Imaging Primer on Chimeric Antigen Receptor T-Cell Therapy for Radiologists
de Groot, P. M., Arevalo, O., Shah, K. B., Strange, C. D., Shroff, G. S., Ahuja, J., Truong, M. T., de Groot, J., & Vlahos, I. (2022) · Radiographics · doi:10.1148/rg.210065 · Cited by 28
Sun, Z., Li, R., Shen, Y., Tan, S., Ding, N., Xu, R., Wang, X., Wei, J., Liu, B., & Meng, F. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01246-y · Cited by 28
Self-citationZhang, Y., Zhou, F., Wu, Z., Li, Y., Li, C., Du, M., Luo, W., Kou, H., Lu, C., & Mei, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.914959 · Cited by 28
Butt, O. H., Zhou, A. Y., Ances, B. M., DiPersio, J. F., & Ghobadi, A. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1110647 · Cited by 28
Xu, L., Wu, P., Rong, A., Li, K., Xiao, X., Zhang, Y., & Wu, H. (2023) · Aging · doi:10.18632/aging.204728 · Cited by 29
Inserting EF1α-driven CD7-specific CAR at CD7 locus reduces fratricide and enhances tumor rejection
Jiang, J., Chen, J., Liao, C., Duan, Y., Wang, Y., Shang, K., Huang, Y., Tang, Y., Gao, X., Gu, Y., et al. (2023) · Leukemia · doi:10.1038/s41375-023-01948-3 · Cited by 28
Self-citationGenetically Stable and Scalable Nanoengineering of Human Primary T Cells via Cell Mechanoporation
Hur, J., Kim, H., Kim, U., Kim, G.-B., Kim, J.-H., Joo, B., Cho, D., Lee, D.-S., & Chung, A. J. (2023) · Nano Letters · doi:10.1021/acs.nanolett.3c01720 · Cited by 28
Approach to the Adult Acute Lymphoblastic Leukemia Patient
Sas, V., Moisoiu, V., Teodorescu, P., Trancă, S., Pop, L., Iluta, S., Paşca, S., Blag, C. L., Man, S. C., Roman, A., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8081175 · Cited by 28
Odejide, O. O., & Steensma, D. P. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30042-9 · Cited by 28
Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms
Holmström, M. O., Hasselbalch, H. C., & Andersen, M. H. (2020) · Cancers · doi:10.3390/cancers12071763 · Cited by 28
Molina, J. C., & Shah, N. N. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003554 · Cited by 29
Chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia.
Badar, T., & Shah, N. N. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-0706-6 · Cited by 27
Treatment strategies for relapse after CAR T-cell therapy in B cell lymphoma
Negishi, S., Girsch, J. H., Siegler, E. L., Bezerra, E. D., Miyao, K., & Sakemura, R. L. (2024) · Frontiers in Pediatrics · doi:10.3389/fped.2023.1305657 · Cited by 27
Andrea, A. E., Chiron, A., Sarrabayrouse, G., Bessoles, S., & Hacein‐Bey‐Abina, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1459818 · Cited by 28
Zhang, C., & Liu, H. (2025) · Journal of Immunology Research · doi:10.1155/jimr/5845167 · Cited by 27
Cytokine release syndrome in solid tumors
Synnott, D., O’Reilly, D., de Freitas, D. G., & Naidoo, J. (2025) · Cancer · doi:10.1002/cncr.70069 · Cited by 27
Sun, W. Y., Mo, X., Zhang, X., Xu, L., Wang, Y., Yan, C., Chen, H., Chen, Y., Han, W., Wang, F., et al. (2018) · Bone Marrow Transplantation · doi:10.1038/s41409-018-0406-z · Cited by 27
Self-citationSuppressive effects of sunitinib on a TLR activation-induced cytokine storm
Zhao, S., Gao, N., Qi, H., Chi, H., Liu, B., He, B., Wang, J., Jin, Z., He, X., Zheng, H., et al. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.04.045 · Cited by 27
Self-citationZheng, S., Asnani, M., & Thomas‐Tikhonenko, A. (2019) · The Cancer Journal · doi:10.1097/ppo.0000000000000381 · Cited by 27
Li, L., Liu, J., Xu, M., Yu, H., Lv, C., Cao, F., Wang, Z., Fu, Y., Zhang, M., Meng, H., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2388-1 · Cited by 27
Zhu, F., Wei, G., Zhang, M., Zhao, H., Wu, W., Yang, L., Hu, Y., & Huang, H. (2020) · Cell Transplantation · doi:10.1177/0963689720919434 · Cited by 28
Neurologic Toxicities of Cancer Immunotherapies: a Review
Harrison, R. A., Tummala, S., & de Groot, J. (2020) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-020-01038-2 · Cited by 27
Davey, A. S., Call, M. E., & Call, M. J. (2020) · Cancers · doi:10.3390/cancers13010038 · Cited by 28
Adoptive Cellular Therapy for Solid Tumors
Bear, A. S., Fraietta, J. A., Narayan, V., O’Hara, M. H., & Haas, N. B. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_321115 · Cited by 31
NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications
Sportoletti, P., Falco, F. D., Papa, B. D., Baldoni, S., Guarente, V., Marra, A., Dorillo, E., Rompietti, C., Adamo, F. M., Ruggeri, L., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136665 · Cited by 29
Xing, H., Yang, X. W., Xu, Y., Tang, K., Tian, Z., Chen, Z., Zhang, Y., Xue, Z., Rao, Q., Wang, M., et al. (2021) · Cytotherapy · doi:10.1016/j.jcyt.2021.05.008 · Cited by 27
Li, P., Zhou, L., Ye, S., Zhang, W., Wang, J., Tang, X., Liu, J., Xu, Y., Qian, W., & Liang, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.638678 · Cited by 27
Cellular immunotherapy for hematological malignancy: recent progress and future perspectives
Xu, Z., & Huang, X. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0801 · Cited by 27
Zhou, B., Chu, X., Tian, H., Liu, T., Liu, H., Gao, W., Chen, S., Hu, S., Wu, D., & Xu, Y. (2021) · American Journal of Hematology · doi:10.1002/ajh.26324 · Cited by 28
Sun, M., Xu, P., Wang, E., Zhou, M., Xu, T., Wang, J., Wang, Q., Wang, B., Lu, K., Wang, C., et al. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.08.014 · Cited by 27
Ando, M., Kondo, T., Tomisato, W., Ito, M., Shichino, S., Srirat, T., Mise‐Omata, S., Nakagawara, K., & Yoshimura, A. (2021) · Cancer Research Communications · doi:10.1158/2767-9764.crc-21-0034 · Cited by 29
Krug, A., Martinez-Turtos, A., & Verhoeyen, E. (2021) · Cancers · doi:10.3390/cancers14010183 · Cited by 28
CAR T cells equipped with a fully human scFv targeting Trop2 can be used to treat pancreatic cancer
Zhu, H., Fang, X., Tuhin, I. J., Tan, J., Ye, J., Jia, Y., Xu, N., Kang, L., Li, M., Lou, X., et al. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04017-x · Cited by 27
Self-citation
Metadata
- Authors
- Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., Roshal, M., Maslak, P., Davila, M., Brentjens, R. J., & Sadelain, M.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- From the Leukemia Service, Department of Medicine (J.H.P., C.S., P.M., R.J.B.), the Michael G. Harris Cell Therapy and Cell Engineering Facility (I.R., X.W., B. Sénéchal, Y.W.), the Center for Cell Engineering (J.H.P., I.R., X.W., R.J.B., M.S.), and the Departments of Epidemiology and Biostatistics (M.G.), Pediatrics (K.J.C.), Neurology (B. Santomasso), Anesthesiology and Critical Care Medicine (E.M.), and Pathology (M.R.), Memorial Sloan Kettering Cancer Center, and the Department of Medicine, Joan...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-02
- Volume
- 378
- Issue
- 5
- Pages
- 449-459
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6637939
- OpenAlex
- W2787621143
- Cited by
- 2,688
- References
- 24
- Citations by year
- 2026: 164 · 2025: 235 · 2024: 306 · 2023: 351 · 2022: 365 · 2021: 403 · 2020: 412 · 2019: 290 · 2018: 156
- FWCI
- 118.36
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Comprehensive Cancer Network Foundation (Young Investigator Award)
- Emerald Foundation
- National Institute of Health (R01CA138738-05, P01CA059350, P01CA190174-01)
- Leukemia and Lymphoma Society (Career Development Award)
- American Society of Clinical Oncology (Career Development Award)
- Memorial Sloan Kettering Cancer Center Support Grant (P30CA008748)
- Juno Therapeutics
- Center for Experimental Therapeutics at Memorial Sloan Kettering Cancer Center
- Stand Up To Cancer
- William Lawrence and Blanche Hughes Foundation
- Annual Terry Fox Run for Cancer Research
- Carson Family Charitable Trust
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CD19 CAR T cells, B-cell acute lymphoblastic leukemia, relapsed leukemia, autologous T cell therapy, cytokine release syndrome, neurotoxicity, disease burden, bone marrow blasts, event-free survival, overall survival, long-term outcomes
- MeSH terms
- Adult, Aged, Follow-Up Studies, Humans, Middle Aged, Receptors, Antigen, T-Cell, Recurrence, Remission Induction, T-Lymphocytes, Survival Analysis, Cytokines, Precursor Cell Lymphoblastic Leukemia-Lymphoma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
